HPV-Testing in follow-up of patients treated for CIN2+ lesions

Luciano Mariani, Maria Teresa Sandri, Mario Preti, Massimo Origoni, Silvano Costa, P. Cristoforoni, Fabio Bottari, Mario Giovanni Sideri

Research output: Contribution to journalArticle

Abstract

Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatment failure, allowing for an intensified monitoring activity. Conversely, women with a neg-ative HPV-test 6 months after therapy have a very low risk for residual/recurrent disease, which leads to a more individualized follow-up schedule, allowing for a gradual return to the normal screening scheme. HPV testing should be routinely included (with or without cytology) in post-treatment follow-up of CIN2+ patients for early detection of recurrence and cancer pro-gression. HPV genotyping methods, as a biological indicator of persistent disease, could be more suitable for a predictive role and risk stratification (particularly in the case of HPV 16/18 persis-tence) than pooled HPV-based testing. However, it is necessary to be aware of the performance of the system, adhering to strict standardization of the process and quality assurance criteria.

Original languageEnglish
Pages (from-to)107-114
Number of pages8
JournalJournal of Cancer
Volume7
Issue number1
DOIs
Publication statusPublished - 2016

Fingerprint

Human papillomavirus 6
Human papillomavirus 18
Human papillomavirus 16
Treatment Failure
Early Detection of Cancer
Cell Biology
Appointments and Schedules
Recurrence
Sensitivity and Specificity
DNA
Therapeutics

Keywords

  • CIN recurrence
  • CIN2+
  • Follow-up
  • Genotyping
  • HPV-testing

ASJC Scopus subject areas

  • Oncology

Cite this

Mariani, L., Sandri, M. T., Preti, M., Origoni, M., Costa, S., Cristoforoni, P., ... Sideri, M. G. (2016). HPV-Testing in follow-up of patients treated for CIN2+ lesions. Journal of Cancer, 7(1), 107-114. https://doi.org/10.7150/jca.13503

HPV-Testing in follow-up of patients treated for CIN2+ lesions. / Mariani, Luciano; Sandri, Maria Teresa; Preti, Mario; Origoni, Massimo; Costa, Silvano; Cristoforoni, P.; Bottari, Fabio; Sideri, Mario Giovanni.

In: Journal of Cancer, Vol. 7, No. 1, 2016, p. 107-114.

Research output: Contribution to journalArticle

Mariani, L, Sandri, MT, Preti, M, Origoni, M, Costa, S, Cristoforoni, P, Bottari, F & Sideri, MG 2016, 'HPV-Testing in follow-up of patients treated for CIN2+ lesions', Journal of Cancer, vol. 7, no. 1, pp. 107-114. https://doi.org/10.7150/jca.13503
Mariani, Luciano ; Sandri, Maria Teresa ; Preti, Mario ; Origoni, Massimo ; Costa, Silvano ; Cristoforoni, P. ; Bottari, Fabio ; Sideri, Mario Giovanni. / HPV-Testing in follow-up of patients treated for CIN2+ lesions. In: Journal of Cancer. 2016 ; Vol. 7, No. 1. pp. 107-114.
@article{c0a3bb3df3784bf7a58a0e7ab791b260,
title = "HPV-Testing in follow-up of patients treated for CIN2+ lesions",
abstract = "Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatment failure, allowing for an intensified monitoring activity. Conversely, women with a neg-ative HPV-test 6 months after therapy have a very low risk for residual/recurrent disease, which leads to a more individualized follow-up schedule, allowing for a gradual return to the normal screening scheme. HPV testing should be routinely included (with or without cytology) in post-treatment follow-up of CIN2+ patients for early detection of recurrence and cancer pro-gression. HPV genotyping methods, as a biological indicator of persistent disease, could be more suitable for a predictive role and risk stratification (particularly in the case of HPV 16/18 persis-tence) than pooled HPV-based testing. However, it is necessary to be aware of the performance of the system, adhering to strict standardization of the process and quality assurance criteria.",
keywords = "CIN recurrence, CIN2+, Follow-up, Genotyping, HPV-testing",
author = "Luciano Mariani and Sandri, {Maria Teresa} and Mario Preti and Massimo Origoni and Silvano Costa and P. Cristoforoni and Fabio Bottari and Sideri, {Mario Giovanni}",
year = "2016",
doi = "10.7150/jca.13503",
language = "English",
volume = "7",
pages = "107--114",
journal = "Journal of Cancer",
issn = "1837-9664",
publisher = "Ivyspring International Publisher",
number = "1",

}

TY - JOUR

T1 - HPV-Testing in follow-up of patients treated for CIN2+ lesions

AU - Mariani, Luciano

AU - Sandri, Maria Teresa

AU - Preti, Mario

AU - Origoni, Massimo

AU - Costa, Silvano

AU - Cristoforoni, P.

AU - Bottari, Fabio

AU - Sideri, Mario Giovanni

PY - 2016

Y1 - 2016

N2 - Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatment failure, allowing for an intensified monitoring activity. Conversely, women with a neg-ative HPV-test 6 months after therapy have a very low risk for residual/recurrent disease, which leads to a more individualized follow-up schedule, allowing for a gradual return to the normal screening scheme. HPV testing should be routinely included (with or without cytology) in post-treatment follow-up of CIN2+ patients for early detection of recurrence and cancer pro-gression. HPV genotyping methods, as a biological indicator of persistent disease, could be more suitable for a predictive role and risk stratification (particularly in the case of HPV 16/18 persis-tence) than pooled HPV-based testing. However, it is necessary to be aware of the performance of the system, adhering to strict standardization of the process and quality assurance criteria.

AB - Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatment failure, allowing for an intensified monitoring activity. Conversely, women with a neg-ative HPV-test 6 months after therapy have a very low risk for residual/recurrent disease, which leads to a more individualized follow-up schedule, allowing for a gradual return to the normal screening scheme. HPV testing should be routinely included (with or without cytology) in post-treatment follow-up of CIN2+ patients for early detection of recurrence and cancer pro-gression. HPV genotyping methods, as a biological indicator of persistent disease, could be more suitable for a predictive role and risk stratification (particularly in the case of HPV 16/18 persis-tence) than pooled HPV-based testing. However, it is necessary to be aware of the performance of the system, adhering to strict standardization of the process and quality assurance criteria.

KW - CIN recurrence

KW - CIN2+

KW - Follow-up

KW - Genotyping

KW - HPV-testing

UR - http://www.scopus.com/inward/record.url?scp=84953858446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953858446&partnerID=8YFLogxK

U2 - 10.7150/jca.13503

DO - 10.7150/jca.13503

M3 - Article

VL - 7

SP - 107

EP - 114

JO - Journal of Cancer

JF - Journal of Cancer

SN - 1837-9664

IS - 1

ER -